Uncommon Descent Serving The Intelligent Design Community

Insane Scaremongering on a Colossal Scale

JVL: If we take the CFR for COVID-19 to be 2% . . . it’s a low estimate . . . in order to exceed Barry‘s limit* of 200,000 deaths in the US there would have to be over 10 million cases in the US. Wikipedia says the 2019 estimated population of the US is about 328 million so that means about 3% of the population would have to be diagnosed. It’s impossible to say, now, of course, but I’d be inclined to think that it’s fairly likely that 3% of the US population will get infected. We’ll see . . . . JVL says “it’s fairly likely that” around 3% of the US population of 328,000,000 will contract COVID Read More ›

The Darwinians show their lovely faces in Brazil

It really doesn’t matter all that much what the accusations are. Right now, Darwinism is a fat living for people who don’t like challenges or thinking too hard. They will do their best to undermine Aguiar Neto, no matter what he does for the average Brazilian science student. And no wonder there is a growing number of populist revolutions in the world. Read More ›

The College Board Exams (Darwin-only evolution) meets COVID-19

Independent journalist Suzan Mazur followed up with the College Board testing on evolution knowledge among U.S. students, which seems to test mainly for familiarity with the Darwin sect’s interpretation. Well, we can spare you the suspense, dear readers, by revealing that they weren't thrilled to hear a critical question. Read More ›

BREAKING: Is the 1934 Bayer anti-malarial, Chloroquine, a potential Covid-19 breakthrough treatment?

And, why is that (which was announced yesterday by Mr Trump) not top- of- fold headline news everywhere? Bayer, US, has announced, March 19: >>Bayer today announced it is joining the U.S. Government’s fight against COVID-19 with a donation of 3 million tablets of the drug Resochin (chloroquine phosphate). Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, also appears to have broad spectrum antiviral properties and effects on the body’s immune response. New data from initial preclinical and evolving clinical research conducted in China, while limited, shows potential for the use of Resochin in treating patients with COVID-19 infection. Bayer in recent days has been in talks with the White House, HHS, Read More ›